Antiviral drugs and monoclonal antibodies to limit Covid damage and hospitalization

“Antiviral drugs and monoclonal antibodies are important to limit the damage from pandemic COVID and hospitalization of patients.”, explains Dr Claudio Zanon, Scientific director of Engine Health, opening the proceedings of the panel: “Early viral treatment to limit the effects of pandemic COVID” of the first day of the Winter School 2022 by Pollenzo, entitled ‘Beyond the logic of silos for an integrated health offer’, organized by Health Engine, In collaboration with theUniversity of Gastronomic Sciences. A high-profile event in health care, promoted and publicized by Mondosanità and from Inside Health,.

Within 5 days of the onset of symptoms

“The problem is that these drugs must be given as soon as possible, within 5 days of the onset of symptoms. All of this is not possible because bureaucracy is very time-consuming and, in fact, limits their use, well below the 1,000 daily administrations initially planned“.

Often times, in fact, the swab arrives after 24 hours and, in case of positivity, the USCA (Special Continuity Care Units) or, in any case, the General Practitioner (GP), should frame the patient and ask the infectious specialist to send him to be able to carry out these therapies, mostly administered in the hospital.

“The solution would be to entrust them to General Practitioners, with possible teleconsultation by the specialist, to shorten the time and administer them according to protocol” concluded Zanon.